Bayer Other Non-Current Liabilities 2010-2024 | BAYRY

Bayer other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Bayer Annual Other Non-Current Liabilities
(Millions of US $)
2023 $15,973
2022 $17,225
2021 $23,967
2020 $17,240
2019 $16,642
2018 $17,693
2017 $12,430
2016 $15,818
2015 $15,715
2014 $20,391
2013 $12,894
2012 $15,135
2011 $14,349
2010 $12,288
2009 $11,782
Bayer Quarterly Other Non-Current Liabilities
(Millions of US $)
2024-06-30 $15,311
2024-03-31 $15,980
2023-12-31 $15,973
2023-09-30 $16,075
2023-06-30 $16,445
2023-03-31 $16,486
2022-12-31 $17,225
2022-09-30 $16,371
2022-06-30 $19,209
2022-03-31 $21,975
2021-12-31 $23,967
2021-09-30 $22,210
2021-06-30 $22,193
2021-03-31 $19,029
2020-12-31 $17,240
2020-09-30 $18,972
2020-06-30 $17,019
2020-03-31 $15,959
2019-12-31 $16,642
2019-09-30 $18,342
2019-06-30 $18,835
2019-03-31 $17,849
2018-12-31 $17,693
2018-09-30 $14,273
2018-06-30 $14,912
2018-03-31 $13,586
2017-12-31 $12,430
2017-09-30 $20,545
2017-06-30 $14,012
2017-03-31 $17,584
2016-12-31 $15,818
2016-09-30 $19,509
2016-06-30 $19,097
2016-03-31 $18,203
2015-12-31 $15,715
2015-09-30 $16,579
2015-06-30 $15,897
2015-03-31 $18,868
2014-12-31 $20,391
2014-09-30 $18,010
2014-06-30 $16,470
2014-03-31 $14,741
2013-12-31 $12,894
2013-09-30 $13,299
2013-06-30 $13,614
2013-03-31 $15,391
2012-12-31 $15,135
2012-09-30 $15,094
2012-06-30 $14,923
2012-03-31 $13,548
2011-12-31 $14,349
2011-09-30 $13,845
2011-06-30 $12,944
2011-03-31 $11,886
2010-12-31 $12,288
2010-09-30 $13,250
2010-06-30 $12,646
2010-03-31 $12,386
2009-12-31 $11,782
2009-09-30 $12,893
2009-06-30 $11,292
2009-03-31 $10,040
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $710.098B 73.55
Novo Nordisk (NVO) Denmark $471.460B 34.00
Johnson & Johnson (JNJ) United States $373.591B 15.15
AbbVie (ABBV) United States $312.696B 16.46
Merck (MRK) United States $250.889B 16.67
Novartis AG (NVS) Switzerland $213.148B 14.17
AstraZeneca (AZN) United Kingdom $203.493B 17.32
Pfizer (PFE) United States $145.358B 9.94
Sanofi (SNY) $122.526B 11.10
Innoviva (INVA) United States $1.199B 9.97